Evidence map›Paper›PMID 37990974›Full record

ArticleMicrobiology (Reading, England)2023

Anti-persister efficacy of colistin and meropenem against uropathogenic

Joanna Urbaniec, Maria Getino, Tahnee B-D McEwan, Martina L Sanderson-Smith, Johnjoe McFadden, Faisal Hai, Roberto La Ragione, Marwa M Hassan, Suzie Hingley-Wilson

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology (Reading, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Bakuchiol killsFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Joanna UrbaniecDepartment of Microbial Sciences, University of Surrey, Guildford, UK.
Maria GetinoSchool of Veterinary Medicine, University of Surrey, Guildford, UK.
Tahnee B-D McEwanMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, Australia.
Martina L Sanderson-SmithMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, Australia.
Johnjoe McFaddenDepartment of Microbial Sciences, University of Surrey, Guildford, UK.
Faisal HaiSchool of Civil, Mining and Environmental Engineering, University of Wollongong, Wollongong, Australia.
Roberto La RagioneDepartment of Microbial Sciences, University of Surrey, Guildford, UK.
Marwa M HassanSchool of Veterinary Medicine, University of Surrey, Guildford, UK.
Suzie Hingley-WilsonDepartment of Microbial Sciences, University of Surrey, Guildford, UK.
University of Surrey · GBUniversity of Wollongong · AU

Funding

Medical Research Council MR/T028998/1
6 · The paper itself

Abstract

Antibiotic persistence is a phenomenon observed when genetically susceptible cells survive long-term exposure to antibiotics. These 'persisters' are an intrinsic component of bacterial populations and stem from phenotypic heterogeneity. Persistence to antibiotics is a concern for public health globally, as it increases treatment duration and can contribute to treatment failure. Furthermore, there is a growing array of evidence that persistence is a 'stepping-stone' for the development of genetic antimicrobial resistance. Urinary tract infections (UTIs) are a major contributor to antibiotic consumption worldwide, and are known to be both persistent (i.e. affecting the host for a prolonged period) and recurring. Currently, in clinical settings, routine laboratory screening of pathogenic isolates does not determine the presence or the frequency of persister cells. Furthermore, the majority of research undertaken on antibiotic persistence has been done on lab-adapted bacterial strains. In the study presented here, we characterized antibiotic persisters in a panel of clinical uropathogenic

Indexed as

Escherichia coli InfectionsUrinary Tract InfectionsUropathogenic Escherichia coliAnti-Bacterial AgentsBacteriaColistinHumansMeropenemAnti-Bacterial AgentsColistinMeropenemantibiotic persistenceantimicrobial resistanceEscherichia coliurinary tract infections

Identifiers

PMID37990974
PMCPMC10710840
OpenAlexW4388912537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.